Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • NPPA fixes prices of...

    NPPA fixes prices of 27 essential formulations

    Written by Ruby Khatun Khatun Published On 2017-12-22T13:13:02+05:30  |  Updated On 22 Dec 2017 1:13 PM IST
    NPPA fixes prices of 27 essential formulations

    New Delhi: National drug pricing regulator NPPA Thursday said it has notified prices of 27 essential formulations, including those used for the treatment of diabetes, blood pressure and pain.


    "NPPA has fixed/revised ceiling prices/Retail Prices of 27 scheduled formulations under Drugs (Prices Control) Order, 2013," it said in a statement.


    NPPA fixes ceiling price of essential medicines of Schedule I under the Drugs (Prices Control) Order (DPCO) 2013.


    In respect of medicines that are not under price control, manufacturers are allowed to increase the maximum retail price by 10 percent annually.


    The calculation of essential drugs is based on the simple average of all medicines in a particular therapeutic segment with sales of more than 1 percent.


    Following are the details


































































































































    Sl. No.Name of the Scheduled
    Formulation /Brand Name
    StrengthUnitManufacturer & Marketing
    Company
    Retail Price (Pre-GST)
    (Rs.)
    Retail Price
    (Post-GST ) (Rs.)
    (1)(2)(3)(4)(5)(6)(7)
    1.Voglibose +
    Metformin
    Each tablet
    contains:
    Voglibose 0.2mg
    Metformin 500mg
    1 TabletM/s Lupin Ltd.4.844.64
    2.Voglibose +
    Metformin
    Each tablet
    contains:
    Voglibose 0.3mg
    Metformin 500mg
    1 TabletM/s Lupin Ltd.5.765.52
    3.Voglibose +
    Metformin+
    Glimepirid
    Each tablet
    contains:
    Voglibose 0.2mg
    Metformin 500mg
    Glimepirid 1mg
    1 TabletM/s Lupin Ltd.7.146.85
    4.Voglibose +
    Metformin+
    Glimepirid
    Each tablet
    contains:
    Voglibose 0.2mg
    Metformin 500mg
    Glimepirid 1mg
    1 TabletM/s Sanofi India
    Ltd.
    7.146.85
    5.Voglibose +
    Metformin+
    Glimepirid
    Each tablet
    contains:
    Voglibose 0.2mg
    Metformin 500mg
    Glimepirid 1mg
    1 TabletM/s Biocon Ltd.7.146.85
    6.Voglibose +
    Metformin+
    Glimepirid
    Each tablet
    contains:
    Voglibose 0.2mg
    Metformin 500mg
    Glimepirid 2mg
    1 TabletM/s Lupin Ltd.9.058.68
    7.Voglibose +
    Metformin+
    Glimepirid
    Each tablet
    contains:
    Voglibose 0.2mg
    Metformin 500mg
    Glimepirid 2mg
    1 TabletM/s Sanofi India
    Ltd.
    9.058.68
    8.Voglibose +
    Metformin+
    Glimepirid
    Each tablet
    contains:
    Voglibose 0.2mg
    Metformin 500mg
    Glimepirid 2mg
    1 TabletM/s Biocon Ltd.9.058.68
    9.Voglibose +
    Metformin+
    Glimepirid
    Each tablet
    contains:
    Voglibose 0.3mg
    Metformin 500mg
    Glimepirid 1mg
    1 TabletM/s Lupin Ltd.8.528.17
    10.Voglibose +
    Metformin+
    Glimepirid
    Each tablet
    contains:
    Voglibose 0.3mg
    Metformin 500mg
    Glimepirid 1mg
    1 TabletM/s Alembic Ltd.8.528.17
    11.Voglibose +
    Metformin+
    Glimepirid
    Each tablet
    contains:
    Voglibose 0.3mg
    Metformin 500mg
    Glimepirid 2mg
    1 TabletM/s Lupin Ltd.10.4610.03
    12.Diclofenac +
    Tramadol
    Each tablet
    contains:
    Diclofenac 75mg
    Tramadol 50mg
    1 TabletM/s Alembic Ltd.9.739.33
































































































































































    Sl. No.Name of the
    Scheduled
    Formulation /Brand Name
    StrengthUnitManufacturer &
    Marketing
    Company
    Retail
    Price
    (Pre-GST)
    (Rs.)
    Retail Price
    (Post-GST ) (Rs.)
    (1)(2) (3)(4) (5)(6)(7)
    1.Glimepiride+ Metformin
    Tablets
    Tablet Contains: Glimepiride 1mg & Metformin 500mg.1 TabletM/s Lupin Limited4.003.84
    2.Glimepiride + Metformin
    Tablets
    Tablet Contains:
    Glimepiride 2mg &
    Metformin 500mg.
    1 TabletM/s Lupin
    Limited
    4.504.32
    3.Metoprolol +
    Chlorthalidone Tablets
    Tablet Contains:
    Metoprolol 25mg &
    Chlorthalidone 12.5mg.
    1 TabletM/s Lupin
    Limited
    5.815.57
    4.Metoprolol+ Chlorthalidone TabletsTablet Contains:
    Metoprolol 25mg &
    Chlorthalidone 12.5mg.
    1 TabletM/s Lupin
    Limited
    5.815.57
    5.Metoprolol +
    Chlorthalidone Tablets
    Tablet Contains:
    Metoprolol 50mg &
    Chlorthalidone 12.5mg.
    1 TabletM/s Lupin
    Limited
    7.226.92
    6.Metoprolol +
    Chlorthalidone Tablets
    Tablet Contains:
    Metoprolol 50mg &
    Chlorthalidone 12.5mg
    1 TabletM/s Lupin
    Limited
    7.226.92
    7.Moxifloxacin+
    Cefixime Tablets
    Tablets contains:
    Moxifloxacin 400mg &
    Cefixime 400mg
    1 TabletM/s Lupin
    Limited
    34.4633.05
    8.Gliclazide +
    Pioglitazone +
    Metformin
    Tablets
    Tablet containing:
    Gliclazide 60mg,
    Pioglitazone 7.5mg &
    Metformin 500mg.
    1 TabletM/s Eris Life
    Sciences Ltd.
    6.255.99
    9.Teneligliptin +
    Metformin
    Tablets
    Tablet Contains:
    Teneligliptin
    Hydrobromide Hydrate eq. to Teneligliptin
    20mg, Metformin HCl
    1000mg.
    1 TabletM/s Eris Life
    Sciences Ltd.
    11.3310.87
    10.Teneligliptin +
    Metformin
    Tablets
    Tablet Contains:
    Teneligliptin
    Hydrobromide Hydrate eq. to Teneligliptin
    20mg
    Metformin HCl 500mg.
    1 TabletM/s Eris Life
    Sciences Ltd.
    10.039.62
    11.Glimepiride +
    Metformin
    Tablets
    Tablet containing:
    Glimepiride 1mg &
    Metformin 1000mg.
    1 TabletM/s Eris Life
    Sciences Ltd.
    5.935.69
    12.Glimepiride +
    Metformin
    Tablets
    Tablet containing:
    Glimepiride 2mg &
    Metformin 1000mg.
    1 TabletM/s Eris Life
    Sciences Ltd.
    7.507.19
    13.Glimepiride +
    Metformin
    Tablets
    Tablet containing:
    Glimepiride 3mg &
    Metformin 1000mg.
    1 TabletM/s Eris Life
    Sciences Ltd.
    8.738.37
    14.Metformin +
    Glimepiride +
    Pioglitazone
    Tablets
    Tablet containing:
    Metformin 500mg,
    Glimepiride 1mg &
    Pioglitazone 15mg.
    1 TabletManufacturer by M/s Jubilant Life Sciences Ltd. and marketed by M/s Hetro Labs Ltd2.232.14
    15.Metformin +
    Glimepiride +
    Pioglitazone
    Tablets
    Tablet containing:
    Metformin 500mg,
    Glimepiride 2mg &
    Pioglitazone 15mg.
    1 TabletM/s Biochem
    Pharmaceuticals Industries Ltd.
    2.452.35


    Below are the attachments for the same.

    http://www.nppaindia.nic.in/ceiling/press20dec17/Prices(12).pdf

    http://www.nppaindia.nic.in/ceiling/press20dec17/Prices(15).pdf

    Medical Dialogues had earlier reported that NPPA had notified prices of 65 essential formulations, including those used for the treatment of diabetes, infections, pain and high blood pressure.

    Read also: NPPA notifies prices of 65 essential formulations
    27 essential formulationsblood pressureceiling pricediabetesDrugs Prices Control Orderessential drugsessential medicinesfixesNational Pharmaceutical Pricing AuthorityNPPApainPrice ControlpricesSchedule IScheduled formulations
    Source : With Agency Inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok